Intelligent Pharma Partners
Pathology AI needs a new business model – and partnering with the pharmaceutical industry is an attractive opportunity
Holger Lange and Cris Luengo |
The true barrier to artificial intelligence (AI) in pathology is not the technology; it’s the business model. To get pathology AI into clinical laboratories, payers need to provide a value-based model that creates a viable business case.
We estimate the US anatomic pathology market for tissue image analysis, based on the current reimbursement model, to be about US$550 million (about $7–8 per test), even though it is unlikely that the Centers for Medicare and Medicaid Services is going to just add $550 million to their reimbursements. The problem is that the anatomic pathology market is segmented into subspecialties, which correspond to different tissue types, each with a list of different tests that typically correspond to different stains. Indeed, myriad “tissue–stain–clinical outcome”-specific tests each have their own little market segment that we estimate to be on average about $11 million, shared by multiple manufacturers.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.